Life after DIAS II.
Donnan
Geoffrey A
GA
National Stroke Research Institute, Heidelberg Repatriation Hospital, Heidelberg Heights, Victoria, Australia. gdonnan@unimelb.edu.au
Davis
Stephen M
SM
D000208:Acute Disease; D017322:Clinical Trials, Phase II as Topic / Q000379:methods / Q000706:statistics & numerical data; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D015424:Reperfusion; D018401:Sample Size; D015983:Selection Bias; D020521:Stroke / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D013997:Time Factors; D017211:Treatment Failure
D005343:Fibrinolytic Agents; C069588:salivary plasminogen activator alpha 1, Desmodus rotundus; D010960:Plasminogen Activators